Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Quality adjusted survival analysis.

P P Glasziou1, R J Simes, R D Gelber

  • 1Department of Public Health, University of Sydney, Australia.

Statistics in Medicine
|November 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].

ESMO open·2024
Same author

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Common genetic variants do not predict recurrent events in coronary heart disease patients.

BMC cardiovascular disorders·2022
Same author

The RECOVERY trial platform: a milestone in the development and execution of treatment evaluation during an epidemic.

Journal of the Royal Society of Medicine·2021
Same author

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same journal

Predictor-Assisted Nonparametric Graphical Models With Multivariate Error-Prone Data.

Statistics in medicine·2026
Same journal

Optimizing Treatment Decision Estimation for Right-Censored Survival Data Through Parameter Transfer Learning.

Statistics in medicine·2026
Same journal

Latent Class Log-Linear Models for Estimating Diagnostic Test Accuracy Without a Gold Standard: A Simulation Study.

Statistics in medicine·2026
Same journal

Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation.

Statistics in medicine·2026
Same journal

Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.

Statistics in medicine·2026
Same journal

Novel Distance Regression for Repeated Outcomes With Missing Data: Applications to Longitudinal and Crossover Studies of Microbiome Beta-Diversity.

Statistics in medicine·2026
See all related articles

Quality-adjusted survival analysis (QASA) offers unbiased estimates for clinical trials with multiple health states. This method accounts for informative censoring, crucial for accurate quality-adjusted life year (QALY) calculations.

Area of Science:

  • Biostatistics
  • Clinical Trial Analysis
  • Health Economics

Background:

  • Standard survival analysis can yield biased estimates in controlled trials with multiple health states due to informative censoring.
  • Quality-adjusted life years (QALYs) are essential for evaluating treatments with varying quality of life outcomes.
  • Existing methods struggle to accurately capture QALYs when patient health states change and data are censored.

Purpose of the Study:

  • To introduce a novel technique, quality-adjusted survival analysis (QASA), for unbiased estimation in controlled trials.
  • To address the challenge of informative censoring in the calculation of quality-adjusted survival.
  • To provide a robust method for analyzing treatment efficacy across different health states.

Main Methods:

Related Experiment Videos

  • Partitioning the survival curve to calculate mean time spent in distinct health states.
  • Multiplying state durations by utility weights to derive unbiased quality-adjusted survival estimates.
  • Employing threshold analysis and confidence bands for robust interpretation when utility weights are uncertain.

    • Main Results:

    • The re-analysis of a breast cancer trial demonstrated the practical application of QASA.
    • Results indicated that chemoendocrine therapy is preferred if the value of time in toxicity outweighs time in relapse.
    • Confidence bands on threshold analysis provide a clear measure of conclusion certainty.

    Conclusions:

    • Quality-adjusted survival analysis (QASA) provides an unbiased method for analyzing controlled trials with multiple health states.
    • The technique effectively handles informative censoring, improving the accuracy of quality-adjusted life year (QALY) calculations.
    • Threshold analysis offers a flexible approach for decision-making when utility values are subject to uncertainty.